Physician profile
Joyce E Yu
NPI 1295948123
$60,975.46
in general payments reported to CMS, 2019-2025
28 companies · $11K in 2025
The $11K reported for 2025 was more than what 89% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,499 · 2020: $9,594 · 2021: $12K · 2022: $10K · 2023: $7,071 · 2024: $6,824 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $7,547 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,236 · Travel and Lodging: $714 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,072.21 |
| Food and Beverage | $7,547.32 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,235.50 |
| Travel and Lodging | $713.84 |
| Education | $108.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $16,506.07 | 2020-2025 | Xembify |
| Csl Behring | $13,521.29 | 2019-2025 | Andembry, Haegarda, Kcentra |
| Genzyme Corporation | $12,777.29 | 2019-2025 | |
| Horizon Therapeutics Plc | $5,497.06 | 2019-2023 | Actimmune |
| Regeneron Healthcare Solutions, INC. | $2,541.89 | 2019-2025 | Dupixent |
| Alk-Abello, INC | $2,381.22 | 2021-2022 | |
| Pharming Healthcare, INC. | $2,284.18 | 2020-2024 | Joenja, Ruconest |
| Astrazeneca Pharmaceuticals Lp | $1,477.06 | 2019-2025 | Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $538.24 | 2022-2025 | Nucala |
| Kaleo, INC. | $533.40 | 2022-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $486.26 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $394.16 | 2025 | Neffy |
| Pfizer INC. | $350.53 | 2019-2023 | |
| Leadiant Biosciences, INC. | $286.04 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $281.18 | 2020-2025 | Cuvitru |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $278.27 | 2022-2024 | Xolair |
| Amgen INC. | $259.80 | 2023-2025 | Actimmune, Tezspire |
| Biocryst US Sales Co., LLC | $135.97 | 2023-2025 | Orladeyo |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Octapharma USA, INC. | $96.62 | 2021 | |
| Sobi, INC | $62.64 | 2023 | |
| Allergan, INC. | $48.13 | 2022 | |
| Shire North American Group INC | $46.18 | 2019 | |
| Dermavant Sciences, INC. | $33.32 | 2024 | Vtama |
| Aimmune Therapeutics, INC. | $21.88 | 2022 | |
| Jubilant Hollisterstier LLC | $19.74 | 2025 | |
| Phadia US INC. | $17.05 | 2023 | Immunocap |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.